Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
Nagaoki Y, Imamura M, Kawakami Y, Kan H, Fujino H, Fukuhara T, Kobayashi T, Ono A, Nakahara T, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Takahashi S, Hayes CN, Ochi H, Chayama K; Hiroshima Liver Study Group.
Nagaoki Y, et al. Among authors: kawaoka t.
Hepatol Res. 2014 Dec;44(14):E447-54. doi: 10.1111/hepr.12336. Epub 2014 May 6.
Hepatol Res. 2014.
PMID: 24690180